Endologix (ELGX +2.3%) presents data from its clinical trial of a totally percutaneous approach...
Monday, January 28, 12:37 PM ETEndologix (ELGX +2.3%) presents data from its clinical trial of a totally percutaneous approach to endovascular abdominal aortic aneurysm repair, says the study demonstrated that the approach is non-inferior to surgical endovascular repair, and also has significantly reduced procedure times and time to hemostasis. The study also demonstrated positive trends toward lower blood loss, less need for pain medication, and shorter lengths of stay.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles